Top Markets
Coin of the day
Bristol-Myers Squibb Company Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY
Rang in aandelen #149
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and... Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Aandeelprijs
$59.43
Marktkapitalisatie
$121.03B
Verandering (1 dag)
0.83%
Verandering (1 jaar)
0.90%
Land
US
Handel Bristol-Myers Squibb Company (BMY)

Categorie

EPS voor Bristol-Myers Squibb Company (BMY)
EPS per December 2025 TTM: $3.46
Volgens de laatste financiële rapporten en de aandelenkoers van Bristol-Myers Squibb Company is de huidige EPS van het bedrijf (TTM) $3.46. Eind 2024 had het bedrijf een EPS van $-4.41, een daling ten opzichte van de EPS van 2023 die $3.88 bedroeg.
EPS-geschiedenis van Bristol-Myers Squibb Company van 2000 tot 2026
EPS aan het einde van elk jaar
Jaar EPS Wijzigen
2026 (TTM) $3.46 0.00%
2025 $3.46 -178.46%
2024 $-4.41 -213.66%
2023 $3.88 30.64%
2022 $2.97 -5.71%
2021 $3.15 -179.15%
2020 $-3.98 -297.03%
2019 $2.02 -33.33%
2018 $3.03 396.72%
2017 $0.61 -77.15%
2016 $2.67 175.26%
2015 $0.97 -19.83%
2014 $1.21 -22.44%
2013 $1.56 33.33%
2012 $1.17 -46.33%
2011 $2.18 20.44%
2010 $1.81 -66.36%
2009 $5.38 103.02%
2008 $2.65 140.91%
2007 $1.10 35.80%
2006 $0.81 -47.40%
2005 $1.54 25.20%
2004 $1.23 -23.13%
2003 $1.60 55.34%
2002 $1.03 -61.85%
2001 $2.70 12.50%
2000 $2.40 0.00%
EPS van vergelijkbare bedrijven of concurrenten
Bedrijf EPS EPS-verschil Land
$23.00 564.74%
US
$13.20 281.50%
GB
$11.10 220.81%
US
$2.37 -31.50%
US
$7.20 108.09%
CH